We have recently made a significant upgrade to the instrumentation we use in our pesticide testing. Knowing what we know about the forth-coming regulatory climate in the California cannabis market, we decided to make a large investment in two brand new SCIEX 3500 triple quadropole mass spectrometers. The greater sensitivity and expanded list of compounds afforded by this new instrumentation will aid us in preparing and empowering our clients to meet and exceed the regulations placed on their businesses by the state of California by this time next year.
On Thursday, the United States government confirmed that Cannabis will continue to be classified as a Schedule I drug, grouping the plant in the same family as such scary substances as Heroin, Cocaine, and Meth.
DEA chief Chuck Rosenberg released a statement on Thursday explaining that a substance is classified as Schedule I when it “has no currently accepted medical use,” that’s recognized by the federal government.
Though this announcement came as no surprise to many advocates of medical marijuana and those fighting for re-classification of the substance, the decision seemed to invoke a collective sigh of exasperation from the cannabis community.
A silver lining may be found in the subsequent parts of the DEA’s announcement, in which the organization suggests it will take action to remove legal hurdles currently in place that are preventing groups from cultivating cannabis to be used for scientific research.
SC Labs President and Co-Founder Joshua Wurzer to speak at Harvard Medical School
It’s conference season and this year Massachusetts-based Medicinal Genomics is bringing together the best and brightest in cannabis for CannMed 2016, a two-day event at Harvard Medical School. Keynote speakers include Raphael Mechoulam, the researcher who discovered THC and Orrin Devinsky, the lead investigator in GW Pharmaceuticals trials using Epidolex for Dravet Syndrome.
The conference comes at a unique time as the advent of sequencing technology has enabled personalized medicine allowing for a better understanding of the genetic regulation of the endocannabinoid system. Conference topics include the use of cannabinoid therapeutics in neurological disorders and the role of the endocannabinoid system in such disorders.
SC Laboratories President Joshua Wurzer will also be presenting a lecture entitled “Chemotypic and Quality Control Analysis of the California Medical Cannabis Market.” Medicinal Genomics also plans to present their hypothesis on the current state of the testing market and its potential impact on the diversity of the cannabis microbiome.
Where: The Joseph B. Martin Conference Center at the Harvard School of Medicine, Boston, MA
When: April 10-11, 2016
More info at: http://www.medicinalgenomics.com/cannmed2016/
Skunky, fruity, floral, the bouquet of smells associated with cannabis can be highly diverse and varied from cultivar to cultivar. This diversity comes from the fragrant molecules found in cannabis called terpenes. There are over a hundred different terpenes found in cannabis, which have evolved with the cannabis plant as a defense mechanism against bacteria, fungi, insects, and other pests. They also serve as the building blocks for more complex molecules like the cannabinoids.
The Chemistry of Terpenes
Terpenes are volatile hydrocarbons that carry an aroma and are made up of small five carbon components called isoprene units. There are also similar molecules found in cannabis called terpenoids, which are modified terpenes where oxygen atoms have been incorporated or methyl groups have been added or removed. Often times the term terpenes is used more broadly to include terpenoids. Terpenes can be further categorized into three different subtypes: monoterpenes, diterpenes, and sesquiterpenes.
Photo taken from: http://www.ochempal.org/wp-content/images/I/isopreneunit.png
Monoterpenes are the simplest type of terpene and are made up of two isoprene…